| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCR2 |
| Uniprot No | P25025 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-360aa |
| 氨基酸序列 | MEDFNMESDSFEDFWKGEDLSNYSYSSTLPPFLLDAAPCEPESLEINKYF VVIIYALVFLLSLLGNSLVMLVILYSRVGRSVTDVYLLNLALADLLFALT LPIWAASKVNGWIFGTFLCKVVSLLKEVNFYSGILLLACISVDRYLAIVH ATRTLTQKRYLVKFICLSIWGLSLLLALPVLLFRRTVYSSNVSPACYEDM GNNTANWRMLLRILPQSFGFIVPLLIMLFCYGFTLRTLFKAHMGQKHRAM RVIFAVVLIFLLCWLPYNLVLLADTLMRTQVIQETCERRNHIDRALDATE ILGILHSCLNPLIYAFIGQKFRHGLLKILAIHGLISKDSLPKDSRPSFVG SSSGHTSTTL |
| 预测分子量 | 66 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CXCR2重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**: *Expression, purification, and functional characterization of recombinant human CXCR2 in insect cells*
**作者**: Jones et al.
**摘要**: 本研究利用杆状病毒-昆虫细胞表达系统成功表达并纯化了功能性人源CXCR2重组蛋白。通过配体结合实验(如IL-8结合)和信号通路检测(钙流实验)，证实重组蛋白具备天然受体的生物活性，为后续药物筛选提供工具。
2. **文献名称**: *Structural insights into CXCR2 activation through recombinant protein crystallography*
**作者**: Smith & Zhang
**摘要**: 通过重组CXCR2蛋白的结晶与结构解析，揭示了其与拮抗剂结合时的构象变化，阐明了跨膜结构域的关键氨基酸残基在信号转导中的作用，为靶向CXCR2的药物设计提供结构基础。
3. **文献名称**: *Development of a high-yield E. coli system for CXCR2 extracellular domain production*
**作者**: Lee et al.
**摘要**: 报道了一种优化的大肠杆菌表达体系，高效表达CXCR2胞外域重组蛋白。通过亲和层析和复性策略获得可溶性蛋白，并验证其与趋化因子(如GRO-α)的结合能力，适用于抗体开发及表位定位研究。
---
注：上述文献为示例性内容，实际引用时需根据具体研究补充真实文献信息。建议通过PubMed或Google Scholar以“CXCR2 recombinant protein expression”等关键词检索最新论文。
CXCR2 (C-X-C chemokine receptor type 2) is a G protein-coupled receptor (GPCR) that plays a central role in inflammatory and immune responses. It binds to CXC chemokines such as CXCL1. CXCL2. CXCL3. CXCL5. CXCL7. and CXCL8 (IL-8), triggering intracellular signaling cascades that regulate leukocyte migration, angiogenesis, and cell survival. CXCR2 is predominantly expressed on neutrophils, monocytes, and endothelial cells, making it a key mediator of neutrophil recruitment to sites of inflammation or injury. Dysregulation of CXCR2 signaling is implicated in chronic inflammatory diseases (e.g., COPD, rheumatoid arthritis), cancer progression (via tumor-associated angiogenesis and metastasis), and autoimmune disorders.
Recombinant CXCR2 protein is engineered for in vitro studies to dissect its structural and functional properties. It is typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, such as glycosylation, which are critical for ligand binding and receptor activation. The recombinant protein often includes tags (e.g., His, FLAG) for purification and detection. Researchers use it to study receptor-ligand interactions, screen therapeutic inhibitors, or map signaling pathways. For example, CXCR2 antagonists are explored as anti-inflammatory or anti-cancer drugs. Structural studies using recombinant CXCR2 have revealed insights into its transmembrane topology and ligand-binding pockets, aiding in rational drug design. However, challenges remain in maintaining its native conformation during purification, as GPCRs are inherently unstable in non-membrane environments. Advances in solubilization techniques (e.g., nanodiscs, detergent optimization) and cryo-EM have enhanced its utility in high-resolution studies. Overall, recombinant CXCR2 serves as a vital tool for understanding inflammation-driven pathologies and developing targeted therapies.
×
